Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
Study Identifier:
D7412C00002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
Date
Jan 2025 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years
Requirements Information
Sex
Female & Male
Age
18 - 130 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
Date
Jan 2025 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
Trial Locations
Location
Status
Location
Research Site
Beijing, China, 100016
Status
Recruiting
Location
Research Site
Dongguan, China, 523059
Status
Recruiting
Location
Research Site
Jinan, China, 250012
Status
Not yet recruiting
Location
Research Site
Shanghai, China, 200040
Status
Recruiting
Location
Research Site
Shenyang, China, 110004
Status
Not yet recruiting
Location
Research Site
Taiyuan, China, 030001
Status
Recruiting